Lantian Lu

Dr. Lantian Lu

Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
Lantian LuLantian Lu
Lantian Lu
VDViet Tram Duong
Viet Tram Duong
ASAhmed O. Shalash
Ahmed O. Shalash
Mariusz SkwarczynskiMariusz Skwarczynski
Mariusz Skwarczynski
Istvan TothIstvan Toth
Istvan Toth
The production of subunit nanovaccines relies heavily on the development of a vaccine delivery system that is safe and efficient at delivering antigens to the target site. Nanoparticles have been extensively investigated for vaccine delivery over the years, as they often possess self-adjuvanting properties. The conjugation of antigens to nanoparticles by covalent bonds ensures co-delivery of these components to the same subset of immune cells in order to trigger the desired immune responses. Herein, we review covalent conjugation strategies for grafting protein or peptide antigens onto other molecules or nanoparticles to obtain subunit nanovaccines. We also discuss the advantages of chemical conjugation in developing these vaccines.

11 June 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
Ye FengYe Feng
Ye Feng
HJHaiping Jiang
Haiping Jiang
MQMin Qiu
Min Qiu
LLLiang Liu
Liang Liu
SZShengmei Zou
Shengmei Zou
FMFan Mo
Fan Mo
Through 4 June 2021, COVID-19 has caused over 172.84 million cases of infection and 3.71 million deaths worldwide. Due to its rapid dissemination and high mutation rate, it is essential to develop a vaccine harboring multiple epitopes and efficacious against multiple variants to prevent the immune escape of SARS-CoV-2. An in silico approach based on the viral genome was applied to identify 19 high-immunogenic B-cell epitopes and 499 human leukocyte antigen (HLA)-restricted T-cell epitopes. Thirty multi-epitope peptide vaccines were designed by iNeo-Suite and manufactured by solid-phase synthesis. Docking analysis confirmed stable hydrogen bonds of epitopes with their corresponding HLA alleles. When four peptide candidates derived from the spike protein of SARS-CoV-2 were selected to immunize mice, a significantly larger amount of total IgG in serum, as well as an increase of CD19+ cells in the inguinal lymph nodes, were observed in the peptide-immunized mice compared to the control. The ratios of IFN-γ-secreting lymphocytes in CD4+ or CD8+ T-cells in the peptide-immunized mice were higher than those in the control mice. There were also a larger number of IFN-γ-secreting T-cells in the spleens of peptide-immunized mice. The peptide vaccines in this study successfully elicited antigen-specific humoral and cellular immune responses in mice. To further validate the safety and efficacy of this vaccine, animal studies using a primate model, as well as clinical trials in humans, are required.

10 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FFFarrhana Z. Firdaus
Farrhana Z. Firdaus
SBStacey Bartlett
Stacey Bartlett
Waleed HusseinWaleed Hussein
Waleed Hussein
Lantian LuLantian Lu
Lantian Lu
QWQuentin Wright
Quentin Wright
Mariusz SkwarczynskiMariusz Skwarczynski
Mariusz Skwarczynski
Human papilloma virus (HPV) is responsible for all cases of cervical cancer. While prophylactic vaccines are available, the development of peptide-based vaccines as a therapeutic strategy is still under investigation. In comparison with the traditional and currently used treatment strategies of chemotherapy and surgery, vaccination against HPV is a promising therapeutic option with fewer side effects. A peptide derived from the HPV-16 E7 protein, called 8Qm, in combination with adjuvants showed promise as a therapeutic vaccine. Here, the ability of polymerized natural amino acids to act as a self-adjuvating delivery system as a therapeutic vaccine was investigated for the first time. Thus, 8Qm was conjugated to polyleucine by standard solid-phase peptide synthesis and self-assembled into nanoparticles or incorporated in liposomes. The liposome bearing the 8Qm conjugate significantly increased mice survival and decreased tumor growth after a single immunization. Further, these liposomes eradicated seven-day-old well-established tumors in mice. Dendritic cell (DC)-targeting moieties were introduced to further enhance vaccine efficacy, and the newly designed liposomal vaccine was tested in mice bearing 11-day-old tumors. Interestingly, these DCs-targeting moieties did not significantly improve vaccine efficacy, whereas the simple liposomal formulation of 8Qm-polyleucine conjugate was still effective in tumor eradication. In summary, a peptide-based anticancer vaccine was developed that stimulated strong cellular immune responses without the help of a classical adjuvant.

8 December 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Lantian LuLantian Lu
Lantian Lu
XLXuehan Lu
Xuehan Lu
WLWei Luo
Wei Luo
Personalized cancer vaccines represent a revolutionary frontier in oncology, harnessing the unique genetic and molecular profile of individual tumors to elicit targeted immune responses. This review provides a comprehensive overview of the current landscape and future perspectives of neoantigen-based personalized cancer vaccines, encompassing peptide, mRNA, DNA, autologous dendritic cell, and viral or bacterial vector platforms. We further discuss the integration of immune adjuvants, delivery systems, and combinational strategies, particularly with immune checkpoint inhibitions, to overcome tumor-induced immune exhaustion and improve therapeutic efficacy. Despite significant clinical progress over the past decade in this space, major challenges remain in immunogenic neoantigens prediction, streamlining individualized vaccine manufacturing, and optimization of combinational regimens to maximize durable antitumor responses. By reviewing recent preclinical and clinical studies on neoantigen-based cancer vaccines, this review highlights key advances, identifies persistent translational bottlenecks, and underscores the need for biomarker-guided mechanistically informed trials to fully unleash the clinical potential of neoantigen-based personalized cancer vaccines in the era of precision immuno-oncology.

18 June 2024 in Vaccine
Verified
Journal Article
Open access
UNUmmey J. Nahar
Ummey J. Nahar
JWJingwen Wang
Jingwen Wang
ASAhmed O. Shalash
Ahmed O. Shalash
Lantian LuLantian Lu
Lantian Lu
TIT. Islam
T. Islam
Mariusz SkwarczynskiMariusz Skwarczynski
Mariusz Skwarczynski
Subunit vaccines require an immunostimulant (adjuvant) and/or delivery system to induce immunity. However, currently, available adjuvants are either too dangerous in terms of side effects for human use (experimental adjuvants) or have limited efficacy and applicability. In this study, we examined the capacity of mannose-lipopeptide ligands to enhance the immunogenicity of a vaccine consisting of polyleucine(L15)-antigen conjugates anchored to liposomes. The clinically tested Group A Streptococcus (GAS) B-cell epitope, J8, combined with universal T helper PADRE (P) was used as the antigen. Six distinct mannose ligands were incorporated into neutral liposomes carrying L15PJ8. While induced antibody titers were relatively low, the ligand carrying mannose, glycine/lysine spacer, and two palmitic acids as liposomal membrane anchoring moieties (ligand 3), induced significantly higher IgG titers than non-mannosylated liposomes. The IgG titers were significantly enhanced when positively charged liposomes were employed. Importantly, the produced antibodies were able to kill GAS bacteria. Unexpectedly, the physical mixture of only ligand 3 and PJ8 produced self-assembled nanorods that induced antibody titers as high as those elicited by the lead liposomal formulation and antigen adjuvanted with the potent, but toxic, complete Freund's adjuvant (CFA). Antibodies produced upon immunization with PJ8 + 3 were even more opsonic than those induced by CFA + PJ8. Importantly, in contrast to CFA, ligand 3 did not induce observable adverse reactions or excessive inflammatory responses. Thus, we demonstrated that a mannose ligand, alone, can serve as an effective vaccine nanoadjuvant.

17 February 2026 in Small
Verified
Journal Article
Open access
Lantian LuLantian Lu
Lantian Lu
JCJazmina L. Gonzalez Cruz
Jazmina L. Gonzalez Cruz
RGRabina Giri
Rabina Giri
YZYuexiao Zhang
Yuexiao Zhang
SBSahra Bashiri
Sahra Bashiri
Mariusz SkwarczynskiMariusz Skwarczynski
Mariusz Skwarczynski
Mixture‐based vaccine formulations offer distinct advantages by eliminating the need for chemical conjugation or complex encapsulations, thereby streamlining preparation, enhancing versatility, and reducing cost and production time. In this study, we report the design of a novel polypeptide‐based self‐assembling adjuvant where a water insoluble 15‐mer polyleucine (L 15 ) is coupled with a polylysine unit (K 6 ). As a nano adjuvant, L 15 K 6 markedly enhances antigen uptake by dendritic cells, promotes antigen‐presenting cell maturation (CD40, CD80/86, and MHC‐II), and upregulates Toll‐like receptor expression, particularly Toll‐like receptor 4 in dendritic cells. Bulk RNA sequencing further reveals robust NF‐κB pathway activation by L 15 K 6 . When co‐delivered with peptide or protein antigens derived from Group A Streptococcus, L 15 K 6 induces robust antigen‐specific IgG response with highly potent antibacterial activity against two clinical Group A Streptococcus strains in vitro. Beyond antigens derived from Group A Streptococcus, L 15 K 6 also enhances immune responses against model protein antigens such as ovalbumin and bovine serum albumin, highlighting its broad applicability. Notably, a single immunization with L 15 K 6 outperforms alum adjuvant in eliciting high levels of bovine serum albumin‐specific IgG. These findings establish L 15 K 6 as a simple yet powerful immunopotentiator with significant promise for the development of broadly applicable subunit vaccines.